The National Health Insurance Civilian Surveillance Alliance yesterday questioned the legitimacy of a certification for pharmaceutical manufacturers after a majority of the manufacturers that were required by the Food and Drug Administration (FDA) to re-file bioequivalence testing (BE) reports for changes made to their products were awarded PIC/S GMP or GMP certification.
BE testing is conducted to ensure that a generic drug delivers the same therapeutic effect as a reference brand-name pharmaceutical.
In response, the agency said that the changes to the drugs were “legitimate” and have no negative impact on drug safety.
Photo: Wei Yi-chia, Taipei Times
At the end of August, the health insurance watchdog held a press conference to report that as many as 3,841 drug products failed to comply with pharmaceutical regulations after making changes to package inserts, packaging and the excipients used in drugs without seeking re-approval by the regulator.
In response, the agency promised to hold risk assessment meetings to evaluate the drugs that had been altered.
This month, the agency announced that 33 out of 3,841 generic drug products would need to be tested for their bioequivalence with brand-name medicines, with 21 more to be examined.
The group found that 10 of the 11 drug manufacturers that produce the 33 drugs are PIC/S GMP (Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme, or the guide to Good Manufacturing Practice for medicinal products) or GMP certified.
“The government has required all pharmaceutical manufacturers to be PIC/S-certified by the end of next year, after which those without will not be permitted to make or sell drugs in Taiwan,” alliance spokeswoman Eva Teng (滕西華) said.
“However, the 10 manufacturers account for 15.8 percent of the 57 PIC/S GMP-certified manufacturers in the country. This makes us concerned that the certification does not guarantee drug quality,” Teng added.
The lack of BE testing reports for drugs that have been altered is a major problem, the group said.
“Changing the excipient, the diluent or the vehicle of a drug could decrease its therapeutic effect,” alliance convener Huang Sue-ying (黃淑英) said, adding that the agency should have ordered that the 33 drug products be pulled off shelves immediately after the announcement this month.
“The agency asked doctors to look for substitutes as soon as possible, and said that the drugs were without health risks,” she said.
FDA official Chi Jo-feng (祁若鳳) said that the PIC/S GMP certificate would not be revoked unless the violations are “grave,” such as producing counterfeit drugs, adding that the drugs were not withdrawn from the market immediately because some patients need time to switch to a new drug.
The agency updated the list in a statement yesterday, announcing the final result of the assessment for the need of BE testing on a total of 54 drugs (including the 33 announced earlier), which said that only nine of the 54 would need to redo BE testing.
One of the 33 drugs required to be tested this month was made exempt because the manufacturer had subsequently handed in relevant documents, while several others decided to revert to the original formula or simply give up the permit for the drug and had their products pulled off shelves, an FDA official said.
Taiwan has received more than US$70 million in royalties as of the end of last year from developing the F-16V jet as countries worldwide purchase or upgrade to this popular model, government and military officials said on Saturday. Taiwan funded the development of the F-16V jet and ended up the sole investor as other countries withdrew from the program. Now the F-16V is increasingly popular and countries must pay Taiwan a percentage in royalties when they purchase new F-16V aircraft or upgrade older F-16 models. The next five years are expected to be the peak for these royalties, with Taiwan potentially earning
STAY IN YOUR LANE: As the US and Israel attack Iran, the ministry has warned China not to overstep by including Taiwanese citizens in its evacuation orders The Ministry of Foreign Affairs (MOFA) yesterday rebuked a statement by China’s embassy in Israel that it would evacuate Taiwanese holders of Chinese travel documents from Israel amid the latter’s escalating conflict with Iran. Tensions have risen across the Middle East in the wake of US and Israeli airstrikes on Iran beginning Saturday. China subsequently issued an evacuation notice for its citizens. In a news release, the Chinese embassy in Israel said holders of “Taiwan compatriot permits (台胞證)” issued to Taiwanese nationals by Chinese authorities for travel to China — could register for evacuation to Egypt. In Taipei, the ministry yesterday said Taiwan
Taiwan is awaiting official notification from the US regarding the status of the Agreement on Reciprocal Trade (ART) after the US Supreme Court ruled US President Donald Trump's global tariffs unconstitutional. Speaking to reporters before a legislative hearing today, Premier Cho Jung-tai (卓榮泰) said that Taiwan's negotiation team remains focused on ensuring that the bilateral trade deal remains intact despite the legal challenge to Trump's tariff policy. "The US has pledged to notify its trade partners once the subsequent administrative and legal processes are finalized, and that certainly includes Taiwan," Cho said when asked about opposition parties’ doubts that the ART was
If China chose to invade Taiwan tomorrow, it would only have to sever three undersea fiber-optic cable clusters to cause a data blackout, Jason Hsu (許毓仁), a senior fellow at the Hudson Institute and former Chinese Nationalist Party (KMT) legislator, told a US security panel yesterday. In a Taiwan contingency, cable disruption would be one of the earliest preinvasion actions and the signal that escalation had begun, he said, adding that Taiwan’s current cable repair capabilities are insufficient. The US-China Economic and Security Review Commission (USCC) yesterday held a hearing on US-China Competition Under the Sea, with Hsu speaking on